
|Videos|March 15, 2016
SGLT2 Inhibitors and Risk for Ketoacidosis and Urinary Tract Infections
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
Advertisement
Susan Cornell, PharmD, CDE, FAPhA, FAADE, describes the risks for ketoacidosis and serious urinary tract infection associated with use of SGLT2 inhibitors.
This video was recorded at APhA's 2016 Annual Meeting and Exposition in Baltimore, Maryland.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Lynkuet Access Program Aims to Help Women Save on Neurokinin-Targeted Therapy
2
FDA Approves Blenrep for Treatment of Relapsed or Refractory Multiple Myeloma
3
Estrogen-Based MHT Does Not Consistently Reduce Anxiety Symptoms in Midlife Women
4
Two Doses of PCV20 in Lymphoma Survivors Elicits Greater Humoral Response
5














































































































































































































